IVVD Invivyd, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1832038 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.3%
TTM net income YoY-117.7%
TTM EPS YoY15.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-224.4%
Net margin-214.8%
FCF margin-221.0%
EBITDA margin—
Returns
ROE-107.0%
ROA-80.7%
ROIC (approx.)-668.6%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets18.2%
Debt / equity0.00x
Current ratio5.51x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.02x
Accruals ratio1.2%
Payout ratio—
Capex / revenue3.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $53.43M | $25.38M | $0 | — | — |
| R&D expense | $38.31M | $137.25M | $158.66M | $179.21M | $182.89M |
| SG&A expense | $66.93M | $63.39M | $49.12M | $47.04M | $36.52M |
| Operating income | -$55.56M | -$176.88M | -$212.76M | -$248.03M | -$226.91M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$52.49M | -$169.93M | -$198.64M | -$241.32M | -$226.79M |
| EBITDA | — | — | -$212.28M | -$247.99M | -$226.91M |
| EPS (basic) | -0.30 | -1.43 | -1.81 | -2.23 | -5.32 |
| EPS (diluted) | -0.30 | -1.43 | -1.81 | -2.23 | -5.32 |
| Weighted avg. shares (diluted) | 172.21M | 118.56M | 109.53M | 108.27M | 42.62M |
| Balance sheet | |||||
| Cash & equivalents | $226.69M | $69.35M | $200.64M | $92.08M | $542.22M |
| Receivables | $13.92M | $10.91M | $0 | — | — |
| Inventory | — | $25.91M | $0 | — | — |
| Current assets | $247.47M | $100.68M | $224.88M | $376.92M | $616.71M |
| PP&E, net | $1.36M | $1.51M | $1.90M | $2.28M | $83,000 |
| Total assets | $276.88M | $129.51M | $229.18M | $383.17M | $620.09M |
| Current liabilities | $34.16M | $61.98M | $50.29M | $25.03M | $62.06M |
| Total liabilities | $35.34M | $61.98M | $51.71M | $27.20M | $62.07M |
| Shareholders' equity | $241.54M | $67.54M | $177.47M | $355.97M | $558.02M |
| Shares outstanding | 281.99M | 119.84M | 110.16M | 109.04M | 110.78M |
| Cash flow statement | |||||
| Operating cash flow | -$58.13M | -$170.49M | -$173.16M | -$219.99M | -$184.74M |
| Capital expenditure | $155,000 | $140,000 | $615,000 | $1.71M | $84,000 |
| Free cash flow | -$58.29M | -$170.63M | -$173.78M | -$221.69M | -$184.82M |
| Investing cash flow | -$155,000 | -$140,000 | $280.68M | -$230.67M | -$50.71M |
| Financing cash flow | $215.63M | $39.33M | $1.04M | $506,000 | $662.68M |
| Depreciation & amortization | — | — | $480,000 | $41,000 | $1,000 |
| Stock-based compensation | $11.64M | $19.79M | $18.68M | $21.65M | $17.76M |
| Share buybacks | — | $0 | $1,000 | $4,000 | $0 |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.